Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 296.45 DKK -0.85% Market Closed
Market Cap: 1.3T DKK

ROCE
Return on Capital Employed

56.8%
Current
73%
Average
2.3%
Industry

ROCE, or Return on Capital Employed, is a financial ratio that measures a company’s profitability in relation to the capital it employs.

ROCE
56.8%
=
EBIT
132.7B
/
Capital Employed
233.5B

ROCE Across Competitors

Country Company Market Cap ROCE
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
57%
US
Eli Lilly and Co
NYSE:LLY
952.1B USD
42%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
2%
US
Johnson & Johnson
NYSE:JNJ
494.4B USD
18%
CH
Roche Holding AG
SIX:ROG
253.5B CHF
31%
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP
18%
CH
Novartis AG
SIX:NOVN
205.7B CHF
25%
US
Merck & Co Inc
NYSE:MRK
245.7B USD
26%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
5%
US
Pfizer Inc
NYSE:PFE
146.6B USD
11%
FR
Sanofi SA
PAR:SAN
101.4B EUR
16%
No Stocks Found

Novo Nordisk A/S
Glance View

In the heart of Denmark, Novo Nordisk A/S stands as a beacon of innovation in the pharmaceutical industry, tracing its roots back to the early 20th century when it began as a small insulin-producing laboratory. This company, now a global heavyweight, is renowned for its dedication to diabetes care, a commitment that has driven its meteoric rise. Novo Nordisk's operations are deeply entrenched in the discovery, development, and production of medicines aimed at treating chronic diseases such as diabetes, obesity, and rare blood and endocrine disorders. Their prowess in biotechnology is not only evident in their diverse product portfolio but also in their relentless pursuit of new therapeutics through cutting-edge research and development, underscoring their mantra of improving the quality of life for millions across the globe. At its core, Novo Nordisk's business model is a sophisticated blend of patient-centric innovation and strategic market outreach. Sales of insulin and GLP-1 receptor agonists form the backbone of their revenue, targeting a growing global demographic faced with diabetes and related metabolic conditions. Their manufacturing process is a finely-tuned system that transforms complex scientific discoveries into tangible, effective treatments. Through strategic pricing, partnerships, and expansion in both mature and emerging markets, Novo Nordisk skillfully maneuvers the intricate web of global healthcare demands. By leveraging a robust pipeline of new drugs and improving access to existing therapies, the company not only secures its financial health but also ensures that its impact on healthcare remains profound and far-reaching.

NOVO B Intrinsic Value
HIDDEN
Show
What is Return on Capital Employed?

ROCE, or Return on Capital Employed, is a financial ratio that measures a company’s profitability in relation to the capital it employs.

ROCE
56.8%
=
EBIT
132.7B
/
Capital Employed
233.5B
What is the ROCE of Novo Nordisk A/S?

Based on Novo Nordisk A/S's most recent financial statements, the company has ROCE of 56.8%.

Back to Top